1. Cultured human alveolar and peritoneal macrophages have been shown to release thromboxane B2 and leukotriene B4.
Introduction
Corticosteroids are employed widely in therapeutics, although until recently their mechanism of action was unknown. Corticosteroids facilitate the transcription of macrocortin, a protein inhibitor of phospholipase Az [l] . This enzyme causes the release of arachidonic acid from phospholipids, and is the rate limiting step in the formation of both the cyclo-oxygenase and lipoxygenase products of arachidonic acid metabolism. Inhibition of the synthesis of prostaglandins, leukotrienes and other potent inflammatory Correspondence: Dr R. W mediators, such as platelet activating factor, may account for the major anti-inflammatory action of corticosteroids [2] . This mechanism has been studied extensively in animals [ 11 and preparations of animal leucocytes [3], but has not been reported previously in preparations of human macrophages that have been purified to near homogeneity, Macrophages are distributed widely in human lung [4] and the peritoneal cavity [5] . The number of macrophages increases during inflammation [6] , and irreversible structural changes due to macrophage activity may underlie the pathology of some pulmonary diseases [7] . Human alveolar macrophages release products of both cyclooxygenase [8] and lipoxygenase [9] metabolism, and the most abundant metabolites of these enzymes are thromboxane Bz and leukotriene B4.
In the present study, the results show release of thromboxane Bz and leukotriene B4 from human alveolar and peritoneal macrophages, with inhibition of release by pretreatment of the cells with dexamethasone.
Materials and methods

Macrop hages
Alveolar macrophages were collected from patients with chronic bronchitis during diagnostic bronchoscopy for suspected lung cancer. The procedure was undertaken with informed written consent. Bronchoalveolar lavage was performed with 200 ml of 0.9% (w/v) NaCl [lo] . None of the patients was receiving steroids or non-steroidal anti-inflammatory drugs.
Cells from the bronchoalveolar lavage were filtered through a fine nylon mesh, and washed twice with Dulbecco's phosphate buffered saline (no Ca2+ or Mg2+ ions) (PBS). The cells were then plated on 25 cm2 culture flasks (Falcon Labware) in 7.0 ml of Dulbecco's modification of Eagle's minimum essential medium (DMEM, Cibco BioCult), containing 10% (v/v) foetal calf serum (Gibco Bio-Cult), gentamicin sulphate (50 pg/ml; Sigma London Ltd) with or without dexamethasone (1 pmol/l: Sigma London Ltd). Flasks were maintained for 16 h in a humidified atmosphere at 37°C containing 10% COz. Microscopic examination (including electron microscopy) of adherent cells from bronchoalveolar lavage prepared by the same method as described have been shown [ 8 ] to contain > 98%' macrophages.
Initial experiments designed t o examine the effect of increasing dexarnethasonc concentrations on thromboxane Bz and leukotriene B4 production by alveolar macrophages were unsuccessful because of the relative paucity of cells. Some experiments were therefore performed with peritoneal macrophages. which could be obtained in much greater numbers. Fluid drained from the peritoneal cavity during peritoneal dialysis usually contains few cells, hence peritoneal fluid samples were only selected when visibly turbid. Samples contained > 40 million microphages/litre, which represented < 10% of the total cell population. By far the most abundant cell types were neutrophil and eosinophil polymorphonuclear leucocytes.
The cells from peritoneal dialysis fluid were resuspended in 10 ml of PBS, layered on 15 nil of Ficoll-Paque [5.7% (w/v) Ficoll 400, 9% (w/v) sodium diatrizoate; Pharmacia], and centrifuged at 400g for 40 min at 18°C. Cells at the interface of the PBS and Ficoll-Paque were removed and washed three times in PBS. The cells were then cultured for 16 h in DMEM (with 108 foetal calf serum and 5 0 pg of gentamicin sulphate/ml) containing selected concentrations of dexamethasone. Microscopic examination of the cells from the gradient revealed them to be > 99% mononuclear cells (macrophages and lymphocytes) and after prolonged culture the adherent cells were >95% macrophages (a few fibroblasts were observed).
Flasks containing either the alveolar or peritoneal cells were then washed three times with DMEM to remove non-adherent cells. The release of throniboxane B, and leukotriene B4 from cultured macrophages was measured by incubation of cells for 3 h in 5 ml of DMEM in the presence or absence of 1.2 mg of opsomized zymosan A/ml.
A flask treated in a similar manner but with no cells added was used as the medium blank for the radioimmunoassays.
Opsonized z.yrnosan A
A suspension of zymosan A (20mg/ml dry weight; Sigma London Ltd) in PBS was opsonized with pooled human serum by incubation at 37°C for 30niin. The opsonized zymosan was then washed three times in PBS.
Measurement of thromboxane B2 and leukotriene
B4
At the end of the 3 h incubation, 4.5 nil of the incubation medium was removed and added to 0.45 ml of Tris-HCI buffer (0.5 mol/l) at pH 7.4. The samples were centrifuged at 3000g for 5 rnin to remove the zymosan A particles. and the supernatants stored at -20°C.
Samples tor analysis were thawed, and from each were takcn two volumes of 2.2 nil.
[3H]-Throinboxane B1 (approx. 3000 c.p.m.) was added to one of the volumes and [3H]leukotriene B4 (approx. 3000 c.p.m.) to the other volume. The fluid was acidified to pH 3.5 with 10% (v/v) formic acid and the arachidonic acid metabolites extracted in 8 ml of distilled ethyl acetate. The organic phase was evaporated to dryness under Nz.
The residue was resuspended in 0.5 ml of water (leukotriene B4) or the Tris-HCI buffer employed in the thromboxane B, radioimmunoassay [ 1 11. An estimation of the recovery of leukotriene B4 (mean 66.3%. range 41.2-78.5%)) and thromboxane B, (mean 83.4%, range 64.0-94.0%) through the extraction procedure was made by counting 100 pl of the resuspended sample.
Thromboxane Bz and leukotriene B4 were measured by radioimmunoassay as reported previously (1 1. 121. Results were corrected for recovery as described. The sensitivity of the leukotriene B4 assay varied between 14 and 26 &assay tube, and that of the thromboxane B2 assay was 2.6 to 7.6 pg/assay tube (confidence limit 2 SD). The leukotriene antibody was obtained from Wellcome Diagnostics (U.K.). The thromboxane antibody and the unlabelled eicosanoids were generous gifts from Dr P. V. Halushka and the Upjohn Co. respectively.
N-A cetyl-D-glu cosam inidase (EC 2.2.1.30) activity
The method employed has been described previously [13] . The protein content of the cultured macrophages was determined by a modification of the method of Lowry er al. [14] , and revealed 3.59 x 106cells/mg of protein (range 3.44-3.78 x lo6).
Statistical analysis
In the text results are expressed as mean f 1 SD, and statistical analysis was performed by using paired Student's t-test where appropriate.
Results
Thromboxane
B2
There was a concentration-dependent reduction in the release of thromboxane B2 by dexamethasone (1 nmol/l to 1 pmol/l) from both unstimulated peritoneal macrophages and those stimulated by opsonized zymosan A. The mean (~s D ) ICso for the inhibition of thromboxane B2 release by dexamethasone in three studies was 3.88k 2.89 nmol/l for the unstimulated cells, and 8 . 5 4 t 4.30 nmol/l for those treated with zymosan A. The release ( m e a n t SD) of thromboxane B2 from cells not treated with dexamethasone was 60.1 (t 2 1.5) and 186 (k45) ng/mg of cell protein. in the absence or presence respectively of opsonized zymosan A.
Experiments with alveolar macrophages were limited to one concentration of dexamethasone because of the relative scarcity of cells. The results are shown in Table 1 . There was a reduction in thromboxane B2 production by both stimulated and unstimulated cells, and this change was significant for the unstimulated cells (P < 0.025). The results did not reach statistical significance for stimulated cells (P<O.l), due partly to the wide variation in the amount of thromboxane B2 produced.
Leukotriene
B4
The concentration of leukotriene B4 in the supernatant of unstimulated peritoneal macrophages was below the sensitivity of the radioimmunoassay . In two experiments, leukotriene B4 was detected after stimulation of the cells with zymosan A. In both there was a concentrationdependent reduction in leukotriene B4 release. The ICs0 values for dexamethasone were 7.06 nmol/l and 2.45 nmol/l. The release (mean) of leukotriene B4 from cells not treated with dexamethasone was <0.2 and 6.4 ng/mg of cell protein, in the absence or presence respectively of opsonized zymosan A.
The amount of leukotriene B4 released from alveolar macrophages is shown in Table 1 . This shows a reduction in leukotriene B4 release after culture in 1 pmol of dexamethasone/l. A time course for the effect of dexamethasone on the The concentration of N-acetylglucosaminidase was increased in the culture medium after stimulation of the macrophages by opsonized zymosan A.
The released enzyme activity of the alveolar and peritoneal macrophages was similar, and dexamethasone caused no change in the release of enzyme.
There was no change in the protein content of the cultured macrophages with increasing dexamethasone concentrations in these experiments.
Discussion
Culture of human peritoneal and alveolar macrophages in the presence of dexamethasone results in a concentration-dependent fall in the release o f both thromboxane B2 and leukotriene B4. The ICs0 for this response was between 1 and 10 nmol/l. These concentrations are within the range achieved in tissue during the clinical use of the drug 1151. The inhibition of arachidonic acid metabolism by corticosteroids has been reported with animal macrophages [3] but never before in human alveolar or peritoneal niacrophages.
Human alveolar macrophages have been implicated in the pathogenesis of certain puhnonary diseases such as emphysema and asthma. Some of these conditions respond to treatment with corticosteroids. The demonstration that dexamethasone inhibits the release of two abundant inflamniatoi-y mediators may explain some of its therapeutic benefit. The mechanism for the inhibition of release of arachidonic acid nietabolites by dexamethasone is probably by production of a protein inhibitor of phospholipase A, [ 1 , 161.
The finding that the 1C5,, values for the inhibition of thromboxane Bz and leukotriene B4 were similar is consistent with a single effector pathway f o r inhibition o f the synthesis of both mediators.
In conclusion, human peritoneal and alveolar macrophages synthesize two important inflammatory mediators, namely thromboxane B2 and leukotriene B4. The release of both compounds is facilitated by the phagocytosis of opsonized zymosan A. Dexamethasone inhibits the release o f thromboxane B2 and leukotriene B4, with no accompanying reduction in the release of the lysosonial hydrolase, N-acetyl-P-D-glucosaminidase.
